OABI
NASDAQOmniAb
$3.08
+0.84 (+37.50%)
2026-08-07 00:00
Healthcare
Biotechnology
--
--
Short Interest (1 Year)
% of Volume Sold ShortMarket Cap
$294.3M
P/E Ratio
N/A
52W Low
52W High
$1.30
$3.12
Volume
2.5M
Analyst Rating
Hold
Target: $7
10 Analyst Ratings
Strong Buy
0
Buy
0
Hold
10
Sell
0
Price Target Range
Low: $7
Avg: $7
High: $7
About OmniAb
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts. Its OmniAb platform's Biological Intelligence powers the immune systems...
Employees
89
Website
omniab.com
Financial Highlights
Annual
Quarterly
| Year | Revenue | Op Margin | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2025 | $18.7M | -383.1% | -$64.8M | -$35.9M |
| 2024 | $26.4M | -282.3% | -$62.0M | -$37.8M |
| 2023 | $34.2M | -203.2% | -$50.6M | $4.0M |
| 2022 | $59.1M | -45.1% | -$22.3M | $13.6M |
| 2021 | $34.7M | -102.5% | -$27.0M | -$1.6M |
| 2026 Q1 | $14.4M | -54.9% | -$7.7M | -$4.7M |
| 2025 Q4 | $8.4M | -186.7% | -$14.2M | -$5.7M |
| 2025 Q3 | $2.2M | -811.3% | -$16.5M | -$9.6M |
| 2025 Q2 | $3.9M | -416.2% | -$15.9M | -$5.0M |
| 2025 Q1 | $4.2M | -453.6% | -$18.2M | -$15.7M |
| 2024 Q4 | $10.8M | -147.0% | -$13.1M | -$3.8M |
| 2024 Q3 | $4.2M | -473.7% | -$16.4M | -$6.4M |
| 2024 Q2 | $7.6M | -214.1% | -$13.6M | -$11.4M |